Stock A352770 CLINOMICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Clinomics Inc.

Equities

A352770

KR7352770002

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/06/2024 BST 		5-day change 1st Jan Change
1,457 KRW -6.60% Intraday chart for Clinomics Inc. -21.33% -43.20%
05-17 Clinomics Inc. announced that it has received KRW 4 billion in funding CI
05-14 Clinomics Inc. announced that it expects to receive KRW 4 billion in funding CI

Business Summary

Clinomics Inc is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood.

Number of employees: 71

Sales per Business

KRW in Million2022Weight2023Weight Delta
Bio
62.0 %
- - 7,077 62.0 % -
Food and Food Service
36.7 %
- - 4,186 36.7 % -
Other
1.3 %
- - 144 1.3 % -
Investment
0.0 %
- - 1 0.0 % -

Sales per region

KRW in Million2022Weight2023Weight Delta
South Korea
100.0 %
23,083 100.0 % 11,408 100.0 % -50.58%

Managers

Managers TitleAgeSince
Jong-Tae Jung CEO
 Chief Executive Officer 62 23/03/21
Byung-Chul Kim CEO
 Chief Executive Officer 59 20/06/11
Sung-Hun Lee CTO
 Chief Tech/Sci/R&D Officer 47 31/12/19

Members of the board

Members of the board TitleAgeSince
Byung-Chul Kim CEO
 Chief Executive Officer 59 20/06/11
Jong-Tae Jung CEO
 Chief Executive Officer 62 23/03/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 38,886,113 33,440,117 ( 86.00 %) 438,977 ( 1.129 %) 86.00 %

Shareholders

NameEquities%Valuation
Xeno Investment Association No 1
12.84 %
4,896,908 12.84 % 7 M ₩
Jong-Hwa Park
6.432 %
2,453,373 6.432 % 4 M ₩
AMICOGEN, INC.
3.066 %
1,169,490 3.066 % 2 M ₩
Byeong-Cheol Kim
1.141 %
435,388 1.141 % 650 936 ₩
CLINOMICS INC.
1.141 %
435,029 1.141 % 650 399 ₩
Byung-Chul Kim
0.5048 %
192,529 0.5048 % 287 844 ₩
Su-wan Cho
0.4802 %
183,159 0.4802 % 273 836 ₩
SALTLUX INC.
0.3733 %
142,394 0.3733 % 212 889 ₩
Jong-Tae Jung
0.3050 %
116,350 0.3050 % 173 951 ₩
Yong-Chul Shin
0.2432 %
92,766 0.2432 % 138 692 ₩

Holdings

NameEquities%Valuation
CLINOMICS INC.
1.14%
 435,029 1.14% 650,399 $

Company contact information

Clinomics, Inc.

50 Unist-Gil, Building 110 Eonyang-eup

44919, Ulsan

+

http://www.clinomics.com
address Clinomics Inc.(A352770)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CLINOMICS INC. Stock Clinomics Inc.
-43.20% 43.26M
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.1B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.76B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 31.24B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.9B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 25.8B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.06B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 13.12B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 10.68B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A352770 Stock
  4. Company Clinomics Inc.